AI assistant
Sending…
Passage BIO, Inc. — Director's Dealing 2022
Nov 14, 2022
34849_dirs_2022-11-14_5ca3ed8f-4fba-43a9-9ee7-7d3f267080a8.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Passage BIO, Inc. (PASG)
CIK: 0001787297
Period of Report: 2022-11-10
Reporting Person: Cale Edgar B. (GC & Corporate Secretary)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2022-11-10 | Restricted Stock Unit | $ | A | 50000 | Acquired | Common Stock (50000) | Direct |
Footnotes
F1: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.
F2: 100% of the total RSUs will vest on December 31, 2023, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
More from Passage BIO, Inc.
Regulatory Filings
2026
May 27
Regulatory Filings
2026
May 26
Interim / Quarterly Report
2026
May 12
Regulatory Filings
2026
Apr 28
Regulatory Filings
2026
Apr 20
Annual Report
2026
Apr 7
Proxy Solicitation & Information Statement
2026
Apr 7
Director's Dealing
2026
Mar 18
Annual Report
2026
Mar 3
Regulatory Filings
2026
Mar 3